%0 Journal Article
%A Schlenk, Richard
%A Weber, Daniela
%A Fiedler, Walter
%A Salih, Helmut R
%A Wulf, Gerald
%A Salwender, Hans
%A Schroeder, Thomas
%A Kindler, Thomas
%A Lübbert, Michael
%A Wolf, Dominik
%A Westermann, Jörg
%A Kraemer, Doris
%A Götze, Katharina S
%A Horst, Heinz-August
%A Krauter, Jürgen
%A Girschikofsky, Michael
%A Ringhoffer, Mark
%A Südhoff, Thomas
%A Held, Gerhard
%A Derigs, Hans-Günter
%A Schroers, Roland
%A Greil, Richard
%A Grießhammer, Martin
%A Lange, Elisabeth
%A Burchardt, Alexander
%A Martens, Uwe
%A Hertenstein, Bernd
%A Marretta, Lore
%A Heuser, Michael
%A Thol, Felicitas
%A Gaidzik, Verena I
%A Herr, Wolfgang
%A Krzykalla, Julia
%A Benner, Axel
%A Döhner, Konstanze
%A Ganser, Arnold
%A Paschka, Peter
%A Döhner, Hartmut
%T Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.
%J Blood
%V 133
%N 8
%@ 0006-4971
%C Stanford, Calif.
%I HighWire Press
%M DKFZ-2019-00681
%P 840 - 851
%D 2019
%X Patients with acute myeloid leukemia (AML) and a FLT3 internal tandem duplication (ITD) have poor outcomes to current treatment. A phase 2 hypothesis-generating trial was conducted to determine whether the addition of the multitargeted kinase inhibitor midostaurin to intensive chemotherapy followed by allogeneic hematopoietic cell transplantation (alloHCT) and single-agent maintenance therapy of 12 months is feasible and favorably influences event-free survival (EFS) compared with historical controls. Patients 18 to 70 years of age with newly diagnosed AML and centrally confirmed FLT3-ITD were eligible: 284 patients were treated, including 198 younger (18-60 years) and 86 older (61-70 years) patients. Complete remission (CR) rate, including CR with incomplete hematological recovery (CRi) after induction therapy, was 76.4
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:30563875
%R 10.1182/blood-2018-08-869453
%U https://inrepo02.dkfz.de/record/143062